Skip to search formSkip to main contentSkip to account menu

BMS-275183

Known as: BMS 275183, BMS275183 
An orally available, C-4 methyl carbonate analog of paclitaxel with potential antineoplastic activity. Like paclitaxel, BMS-275183 binds to tubulin… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Bridged-Ring Compounds
Microtubule Process

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies
SummaryPurpose BMS-275183 is an oral C-4 methyl carbonate analogue of paclitaxel that has the same mechanism of action… 
2009
2009
Metabolism and Excretion of an Oral Taxane Analog, [14C]3′-tert-Butyl-3′-N-tert-butyloxycarbonyl-4-deacetyl-3′-dephenyl-3′-N-debenzoyl-4-O-methoxy-paclitaxel (BMS-275183), in Rats and Dogs
3′-tert-Butyl-3′-N-tert-butyloxycarbonyl-4-deacetyl-3′-dephenyl-3′-N-debenzoyl-4-O-methoxy-paclitaxel (BMS-275183) is a taxane… 
2009
2009
CYP3A4-Mediated Ester Cleavage as the Major Metabolic Pathway of the Oral Taxane 3′-tert-Butyl-3′-N-tert-butyloxycarbonyl-4-deacetyl-3′-dephenyl-3′-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS…
3′-tert-Butyl-3′-N-tert-butyloxycarbonyl-4-deacetyl-3′-dephenyl-3′-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS-275183) is an… 
Review
2009
Review
2009
Epothilones: better or more of the same?
Agents that interfere with microtubule structure and function continue to play a major role in cancer treatment. The vinca… 
2008
2008
Effect of Food on the Pharmacokinetic Behavior of the Potent Oral Taxane BMS-275183
Purpose: BMS-275183 is a potent oral paclitaxel analogue that previously showed promising activity. The goal of the present trial… 
2007
2007
A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183
Purpose: BMS-275183, an orally administered C-4 methyl carbonate paclitaxel analogue, showed promising activity in a phase I… 
Highly Cited
2004
Highly Cited
2004
Therapeutic Synergy of Oral Taxane BMS-275183 and Cetuximab versus Human Tumor Xenografts
Purpose: Combination therapy consisting of an oral taxane, BMS-275183, and the anti-epidermal growth factor receptor monoclonal… 
2004
2004
A phase I trial of the novel oral taxane BMS-275183 in patients with advanced solid tumors.
2029 Background: BMS-275183, a novel orally administered taxane, has been studied in this phase I trial to assess its safety… 
2003
2003
The discovery of BMS-275183: an orally efficacious novel taxane.
Highly Cited
2001
Highly Cited
2001
Preclinical pharmacology of BMS-275183, an orally active taxane.
BMS-275183 is a taxane, the mechanism of action of which is like other known taxanes, and is the polymerization of tubulin. BMS… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)